Biology subjects

Call, M. J.

Publications and source records attributed to Call, M. J..

4 recordsLinked to original sources

bioRxiv2025

Shared and distinct sequence-function signatures define different modes of human TpoR activation

The human thrombopoietin receptor (hTpoR) exists primarily as JAK2-associated monomers that become activated when converted to dimeric forms that support JAK trans-phosphorylation. This can be achieved by several different modes of stimuli, including the natural ligand Tpo, biologic agonists that bind the same site as Tpo, small-molecule drugs that bind the transmembrane (TM) domain, oncogenic mutations in and near the TM domain, and by association with constitutively active JAK V617F or a mutant form of the chaperone protein calreticulin. It is unclear how the dimeric structures induced by synthetic agonists and mutations relate to one another, and whether any of these induce the same active structure as the native ligand Tpo, yet this has important implications both for fundamental cytokine receptor biology and for development of targeted interventions for hTpoR-driven myeloproliferative diseases. Here we used deep mutational scanning (DMS) across the TM and juxtamembrane (JM) regions of hTpoR to extract feature-rich sequence-function signatures across a variety of different activating contexts. While each displayed some unique features, synthetic agonists and activating mutations all exhibited strong dependence on a common TM interface that is consistent with previous models of a left-handed, near-parallel helix dimer with H499 facing lipid. In contrast, Tpo-mediated activation was broadly insensitive to TM-JM substitutions, indicating that it does not rely on the same interface. Modeling with AlphaFold 3 (AF3) consistently yielded a right-handed, "splayed" helix dimer that is close at the extracellular face, contains H499 in the interface and diverges toward the cytosolic face, resting on an intracellular amphipathic JM helix that lies parallel to the membrane, which is also observed in a DMS/AF3 analysis of human erythropoietin receptor. This splayed Tpo-bound dimer could be stably inserted into a lipid bilayer with associated JAK2 using molecular dynamics and is supported by experiments showing that most or all of the TM domain can be replaced by poly-valine, with little effect on Tpo-driven activation but catastrophic effects on responses to synthetic ligands. Our data support at least two different structural modes of hTpoR activation that reconcile prior biochemical models, rationalize patient variants, and inform mechanism-based agonist and antagonist design.

biochemistry↗

bioRxiv2025

Deep learning-based joint sequence-structure de novo membrane protein design

Deep learning has revolutionized soluble protein design, yet de novo transmembrane (TM) protein engineering remains hindered by scarce structural data, complex membrane-specific interactions and conformational dynamics. We developed TMDiffusion (TMDF), a joint all-heavy-atom sequence-structure diffusion model trained to capture the full interaction diversity of natural TM proteins, including weak and polar contact networks. TMDF designs diverse TM architectures--associating domains, inhibitors, and conformational switches--in a single step, achieving >70% experimental success. A crystal structure of designed proteins matches predictions with atomic accuracy. Leveraging TMDF, we built synthetic single-pass receptors whose de novo TM domains toggle between conformations, enabling precise control of signalling outputs consistent with predicted equilibria. These results show that membrane-adapted DL models can accurately encode and program TM association energetics and conformations. TMDF establishes a general framework for bottom-up design of TM proteins with programmable functions, advancing both mechanistic studies of membrane proteins and development of next-generation therapeutics.

biophysics↗

bioRxiv2024

Mutational Profiling of SARS-CoV-2 PLpro in human cells reveals requirements for function, structure, and drug escape

SARS-CoV-2, the causative agent of COVID-19, is responsible for the recent global pandemic and remains a major source of mortality. Papain-like protease (PLpro) is a target for SARS-CoV-2 inhibitor development, as it is not only essential for viral replication through cleavage of the viral poly-proteins pp1a and pp1ab, but also has de-ubiquitylation and de-ISGylation activities, which can affect innate immune responses. To understand the features of PLpro that dictate activity and anticipate how emerging PLpro variants will affect function, we employed Deep Mutational Scanning to evaluate the mutational effects on enzymatic activity and protein stability in mammalian cells. We confirm features of the active site and identify all mutations in neighboring residues that support or ablate activity. We characterize residues responsible for substrate binding and demonstrate that although the blocking loop is remarkably tolerant to nearly all mutations, its flexibility is important for enzymatic function. We additionally find a connected network of mutations affecting function but not structure that extends far from the active site. Using our DMS libraries we were able to identify drug-escape variants to a common PLpro inhibitor scaffold and predict that plasticity in both the S4 pocket and blocking loop sequence should be considered during the drug design process.

biochemistry↗

bioRxiv2020

De novo designed receptor transmembrane domains enhance CAR-T cell cytotoxicity and attenuate cytokine release

De novo designed receptor transmembrane domains (TMDs) present opportunities for precise control of cellular receptor functions. We developed a de novo design strategy for generating programmed membrane proteins (proMPs): single-pass -helical TMDs that self-assemble through computationally defined and crystallographically validated interfaces. We used these proMPs to program specific oligomeric interactions into a chimeric antigen receptor (CAR) and found that both in vitro CAR T cell cytokine release and in vivo antitumor activity scaled linearly with the oligomeric state encoded by the receptor TMD, from monomers up to tetramers. All programmed CARs (proCARs) stimulated substantially lower T cell cytokine release relative to the commonly used CD28 TMD, which we show elevated cytokine release through lateral recruitment of the endogenous T cell costimulatory receptor CD28. Precise design using orthogonal and modular TMDs thus provides a new way to program receptor structure and predictably tune activity for basic or applied synthetic biology.

synthetic biology↗